2013 Korean Society of Hypertension guidelines for the management of hypertension: part I–epidemiology and diagnosis of hypertension by Jinho Shin et al.
Shin et al. Clinical Hypertension  (2015) 21:1 
DOI 10.1186/s40885-014-0012-3REVIEW Open Access2013 Korean Society of Hypertension guidelines
for the management of hypertension: part I–
epidemiology and diagnosis of hypertension
Jinho Shin1, Jeong Bae Park2, Kwang-il Kim3, Ju Han Kim4, Dong Heon Yang5, Wook Bum Pyun6,
Young Gweon Kim7, Gheun-Ho Kim1, Shung Chull Chae5*, The Guideline Committee of the Korean Society
of Hypertension
This article is 1/3, Please see related article 10.1186/s40885-014-0012-3Abstract
The standardized techniques of blood pressure measurement in the clinic are emphasized and the indications for
ambulatory and/or home blood pressure monitoring are specified more broadly. The epidemiologic findings
specific to Korean population related to blood pressure are reviewed. Cardiovascular risk of hypertensive patients
are stratified based upon the data of a Korean population cohort study.
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Since the publication of the last Korean Hypertension
Treatment Guideline in 2004, new studies have been re-
leased and new data on antihypertensive drugs introduced.
In response to the changes, the Guideline Committee of
the Korean Society of Hypertension began to revise its
guideline. To perfectly tailor the needs of our clinical prac-
tices, the guideline needs to be based on a great deal of
studies performed in Korea. Unfortunately, in reality, there
is currently a serious shortage of such study results. The
Committee therefore decided to establish the guideline in
the form of adaptation. The recently released guideline on
hypertension from the European Society of Hypertension/
the European Society of Cardiology which is designed to
encompass the diverse cardiovascular disease risk levels
and socioeconomic statuses of the member nations, and
which, therefore, has a broad scope of recommenda-
tions, was chosen as a model. Accordingly, a large por-
tion of the 2013 Korean guidelines is based on the* Correspondence: scchae@knu.ac.kr
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adjustments are made.
Epidemiology of hypertension
The classification of blood pressure and hypertension
Hypertension (HTN) is defined as systolic blood pres-
sure (SBP) or diastolic blood pressure (DBP) greater
than or equal to 140 or 90 mm Hg, respectively (Table 1).
Normal blood pressure (BP) is defined only as both SBP
less than 120 mm Hg and DBP less than 80 mm Hg.
When SBP is greater than or equal to 120 but below
140 mm Hg and/or DBP is greater than or equal to 80
but below 90 mm Hg, the patient is considered to have
prehypertension. Prehypertension is further classified as
stage 1 and stage 2 prehypertension. In stage I prehyper-
tension, SBP is greater than or equal to 120 but below
130 mm Hg and/or DBP is greater than or equal to 80
but below 85 mm Hg. In stage 2 prehypertension, SBP is
greater than or equal to 130 but below 140 mm Hg and/
or DBP is greater than or equal to 85 but below 90 mm Hg.
When SBP is greater than or equal to 140 mm Hg and
DBP is below 90 mm Hg, the patient is said to have
isolated systolic HTN. HTN is further classified as stage
1 and stage 2 HTN. In stage 1 HTN, SBP is belowis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The classification of blood pressure and hypertension
Category Systolic blood pressure (mm Hg) Diastolic blood pressure (mm Hg)
Normal blood presssurea <120 And <80
Prehypertension Stage 1 120–129 Or 80–84
Stage 2 130–139 Or 85–89
Hypertension Stage 1 140–159 Or 90–99
Stage 2 ≥160 Or ≥100
Isolated systolic hypertension ≥140 And <90
aBlood pressure with minimal risk for cardiovascular events.
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SBP/DBP is greater than or equal to 160/100 mm Hg.The risk of high blood pressure
There has been no prospective observational study of a
general population to prove the risk of high BP in Koreans.
Normal BP has been established as the reference level of
BP with the lowest level of cardiovascular (CV) risk in
evaluation of the risk of high BP. In the best-documented
domestic study of the risk of high BP, which enrolled ap-
proximately 100,000 male civil officers and private school
teachers (Korean Medical Insurance Corporation [KMIC]
study), the hazard ratio for cerebrovascular and coronary
artery disease during a 6-year follow-up period was 2.6 for
the HTN group relative to the subjects with BP less than
130/85 mm Hg [1,2]. In the nested 248 patient case-control
study from the KMIC studies, HTN was the most import-
ant risk factor for stroke. Furthermore, the risk of coronary
artery disease was 2.51-fold higher in the stage 2 prehyper-
tension group than that in the stage 1 prehypertension
group. The group with HTN of greater than or equal to
180/110 mm Hg exhibited a 5.08-fold higher risk than the
stage 1 prehypertension group [2,3]. In both Asian and
western populations, lifestyle tends to be worse with re-
spect to CV health in subjects with prehypertension than
in those with normal BP. In addition, the probability of pro-
gressing to HTN and the risk for a CV event were both re-
ported to be higher in the prehypertension group than
those in the normal BP group [4-6]. In another paper from
the KMIC study, a BP higher than 135/85 mm Hg was as-
sociated with the occurrence of hemorrhagic stroke (intra-
cerebral hemorrhage and subarachnoid hemorrhage) in
male subjects. As shown in Figure 1, the attributable risks
by HTN for cerebrovascular disease and coronary artery
disease in men were 35% and 21%, respectively [7]. In
addition, for each 20 mm Hg increase in SBP, the relative
risks of ischemic stroke, intracerebral hemorrhage, and
subarachnoid hemorrhage were 1.79, 2.48, and 1.65, re-
spectively, in men and 1.64, 3.15, and 2.29, respectively, in
women [7]. Therefore, the risks of high BP for stroke and
coronary artery disease in Korea have been welldocumented. Moreover, the risk of stroke is more attribut-
able than that of coronary artery disease to HTN.
The prevalence of hypertension
In the Korean National Health and Nutrition Examination
Survey (KNHANES), the age-standardized prevalence of
HTN, defined as SBP/DBP of 140/90 mm Hg or higher,
was approximately 30% among adults over 30 years of age.
Changes in the prevalence of hypertension
As shown in Table 2, the prevalence of HTN from the
KNHANES was 29.9% and 28.6% in 1998 and 2001, re-
spectively. This figure decreased slightly in 2007 and
2008 and then increased again in 2011. The changes in
the prevalence during this period are mainly due to fac-
tors other than the true prevalence, such as changes in
the survey fields or circumstances [8]. Among adults
aged 65 years or older, the prevalence increased between
2007 and 2011 from 49.3% to 58.4% in men and from
61.8% to 68.9% in women. The prevalence of prehyper-
tension in 2001 was 39.8% in men and 30.6% in women.
These figures decreased slightly, to 28.4% in men and
18.8% in women, in 2008, similar to the trend in the
prevalence of HTN. Overall, less than half of the Korean
population has normal BP.
Age and sex differences in blood pressure
BP rises with age, and the difference in BP between the
sexes diminishes among those aged more than 60 years.
The prevalence of HTN is more than 50% in this older
population, i.e., 60 or more years (Figure 2). In general,
the prevalence of HTN is 5% to 10% higher in men than
in women. Among postmenopausal women, BP in-
creases so rapidly with age that the sex difference be-
comes trivial within a decade [9].
In KNHANES 2005, the prevalence of HTN among
the elderly was 53.7% among those in their 60s and
54.9% among those in their 70s. The prevalence of HTN
among those in their 60s was 53.8% in men and 53.6%
in women, showing that the sex difference disappeared
among those aged 60 or older. As shown in KNHANES
2011, SBP steadily increase with age more than 60 years
Figure 1 Attributable risks of hypertension and other cardiovascular risk factors for the coronary artery disease (A) and cerebrovascular
diseases (B) in Korean male population (Korean Medical Insurance Corporation study).
Shin et al. Clinical Hypertension  (2015) 21:1 Page 3 of 11(Figure 2), whereas DBP decrease, resulting in an in-
crease in the pulse pressure [10].The relationship between salt intake and blood pressure
Reducing salt intake is known to decrease BP. Reduction
of salt intake is important because the estimated daily
salt intake according to KNHANES is approximately
12 g [11]. The report showed that salt intake was higher
in the group younger than 40 years than in the other age
groups in the cross-sectional analysis of data from 1998,
2001, and 2005. No relationship between salt intake and
BP remained after adjustment for energy intake in this
analysis [12-14]. However, an independent association
between salt intake and BP was reported among people
with metabolic syndrome [12-15]. In addition, the urin-
ary sodium/creatinine ratio is more clearly associated
with the BP level than with salt intake [16]. Because the
salt intake in KNHANES was estimated by using a food
questionnaire, which has limited accuracy, and because
it is a cross-sectional analysis including both patients
with HTN who have not yet changed their diet as well
as those who changed their eating habits after diagnosis,
additional research is needed. In western countries, re-
duction of salt intake is reported to lower BP regardless
of the relationship between salt intake and BP in the
cross-sectional study. There has been no prospectiveTable 2 Trends in the prevalence of hypertension in the popu
1980a 1990a 1998b 200
All 29.9 28.6
Men 35.5 33.2 32.5 33.2
Women 26.9 25.4 26.9 25.4
Values in % and modified from 2011 Korean National Health Statistics.
aThe prevalence in 1980 and 1990 were based on the nationwide study for hyperte
bAge adjusted for the estimated population in 2005.study in Korea to document the BP-lowering effect of a
reduction in salt intake.
Metabolic syndrome and hypertension
In data from the general population in the period from
1998 to 2005, the prevalence of metabolic syndrome, for
which the diagnostic criterion for abdominal obesity was
a waist circumference of 90 cm in men and 80 cm in
women, was reported to be 24.1%, having increased from
22.5% in 1998 to 24.1% in 2001 [17]. High BP is the
main component of the metabolic syndrome in men and
was observed in 40% of subjects. In women, the low
high-density lipoprotein (HDL) cholesterol component
was most prevalent (59%), followed by the high BP com-
ponent observed in 30% of female subjects [18]. Based
on the data from KNHANES 2001 and 2005, the preva-
lence of metabolic syndrome in patients with HTN and
prehypertension was 53.3% and 26.2%, respectively, both
of which were significantly higher than the 24.1% preva-
lence in the general population [19]. Metabolic disorder
is a determinant of progression from prehypertension to
overt HTN [20,21] and thus the key target for lifestyle
modification.
Status of the management of hypertension
In general, it is important to monitor the rates of aware-
ness, treatment, and control of HTN, as these are thelation aged >30 years
1b 2005b 2007b 2008b 2011b
28.0 24.6 26.3 28.5
31.5 26.9 28.1 32.9
23.9 21.8 23.9 23.7
nsion.
Figure 2 Levels of blood pressure according to the age groups in male and female Korean populations (2011 Korean National Health
and Nutrition Examination Survey data). DBP diastolic blood pressure, SBP systolic blood pressure.
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respect to public health. The HTN awareness rate is de-
fined as ‘the proportion of the subjects who are aware of
their physician-diagnosed HTN among all of the subjects
with HTN.’ The rate of treatment of HTN is defined as
‘the proportion of the subjects taking antihypertensive
drugs at the time of the survey among all of the subjects
with HTN.’ The control rate is defined as ‘the propor-
tion of the subjects with BP controlled below 140/
90 mm Hg among the subjects taking antihypertensive
drugs or among all subjects with HTN.’
The awareness, treatment, and control rates in South
Korea are generally improving. According to the data
from KNHANES during the period from 2008 to 2011,
the awareness rate was 58.5% and 76.1% among men
and women aged over 30 years, respectively, which was
an improvement relative to the previous data (Table 3).
The rate of HTN treatment in 2001 was 22.2% and
37.5% in men and women, respectively, according to the
in-depth report of KNHANES 2005. This rate improved
to 51.7% and 71.3% among men and women, respect-
ively, in the 2008 to 2011 period (Table 3). The rate of
control of HTN in 2001 was quite low at 9.9% and





Control rate for all hypertension patients 7.4
Control rate for treated hypertension patients 22.9
Values in % and standardized for census 2005, Korean National Health Statistics. Cri
20 days per month.of the 2008 to 2011 period, it had increased to 36.9%
and 49.4% among men and women, respectively
(Table 3). Although there was no clear change in the
prevalence of HTN, the mean BP has steadily decreased,
especially among patients with HTN.
The changes in these indicators suggest that the over-
all management of HTN has improved. However, the
rates of awareness, treatment, and control are relatively
low among young men in their fourth decade and need
further improvement. Despite the low control rate in the
young subjects, the control rate among those being
treated for HTN did not differ among the age groups.
Therefore, early detection and treatment of HTN in
younger individuals is very important [8]. According to
the 2007 KNHANES data, the proportion of the subjects
actively performing three or more of the listed lifestyle
modifications (weight control, regular exercise, moder-
ation of alcohol intake, reduction of salt intake, and
smoking cessation) was only 38.2% among patients with
HTN aged 40 years or older. A campaign or other edu-
cation to improve lifestyle modification compliance re-
mains warranted. The treatment rate among patients in
their 70s is similar to that among those in their 60s, but






terion for treatment of hypertension: taking antihypertensive drug more than
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their 70s. These findings suggest that more active diag-
nosis and treatment of HTN in patients aged 70 years or
older is needed.
White coat hypertension and masked
hypertension
‘White coat HTN’ is diagnosed when the patient’s BP in
the medical office is 140/90 mm Hg or above but the
daytime ambulatory or home BP is less than 135/85 mm
Hg. If the BP is high both in and out of the office, the
patient is considered to have ‘persistent HTN.’ Accord-
ing to the registry data for ambulatory BP monitoring
(ABPM) in secondary or tertiary referral centers sup-
ported by the Korean Society of Hypertension (KorABP
registry) [22], 14.9% of 1,916 subjects who underwent
ABPM for the diagnosis of HTN were found to have
white coat HTN, as were 25.3% of subjects with HTN
diagnosed on the basis of the office BP. In single-center
studies from a domestic tertiary hospital, white coat
HTN occurred more frequently in women and in men
with a low body mass index (BMI) [23]. According to
the KorABP registry data, the proportion of subjects in
whom daytime ambulatory BP was lower than 135/
85 mm Hg and office BP higher than 140/90 mm Hg
was 13.5% among all treated subjects and 21.3% among
subjects with uncontrolled HTN by office BP [22].
‘Masked HTN’ is defined as the condition in which the
office BP is less than 140/90 mm Hg and the daytime
ambulatory BP or home BP is 135/85 mm Hg or higher.
According to the KorABP registry data, masked HTN
was observed in 17.6% of patients who underwent
ABPM for the diagnosis of HTN [22]. Masked HTN was
also observed in 13.8% of patients taking antihyperten-
sive medication and in 35.1% of subjects with controlled
office BP. In a domestic study performed in primary care
clinics, the prevalence of masked HTN was 21.2%, and
male sex, elderly age, and smoking were the independent
predictors of masked HTN [24]. Treatment of HTN in a
tertiary care center, number of pills, and a higher fasting
blood glucose level have also been associated with
masked HTN [25].
There has been no study of white coat HTN and masked
HTN in a Korean general population. A study in a western
population showed that white coat HTN carries a good
prognosis over a follow-up period of 5 years but is associ-
ated with increased risk for the onset of HTN and occur-
rence of CV events over the long-term; therefore, patients
with white coat HTN should be monitored regularly [26].
In foreign studies, masked HTN has a similar prognosis as
persistent HTN both in the general population and in pa-
tients with treated HTN [27,28]. A Korean study reported
more severe myocardial damage in patients with masked
HTN than in those with white coat HTN [29].Diagnosis and clinical evaluation
Blood pressure measurement
Accurate measurement of BP is necessary for the diag-
nosis, treatment, and prognostication of individuals with
high BP. BP varies according to the environment, body
part, and clinical setting of measurement. Therefore, the
measurement should be repeated and a standard method
should be used.
Measurement of the office or clinic blood pressure
In an office or clinic, BP is usually measured by the aus-
cultation method using a stethoscope. The subject is
seated on a chair with his or her back supported. The
cuff is placed on the upper arm and maintained at the
level of the heart. A mercury or calibrated aneroid
sphygmomanometer is used. An automatic sphygmo-
manometer that has been validated may also be used.
The use of mercury sphygmomanometers is decreasing
because of the risk of environmental mercury pollution.
The use of an automatic sphygmomanometer is recom-
mended in some countries. After the patient has rested
for five or more minutes, the BP is measured by the aus-
cultation method. The measurement is performed two
or more times. A cuff with an appropriately sized blad-
der should be used. The standard bladder for adults is
13 cm wide and 22 to 24 cm long. The use of a bladder
with a width of at least 40% of the circumference of the
arm and a length of 80% to 100% of the circumference
of the arm is recommended.
A cuff of appropriate size as recommended by the
manufacturer should be used. A cuff that is too small
can produce an artificially high BP reading, whereas a
cuff that is too large can produce an artificially low BP
reading. If the pulses of the lower extremities are weak,
BP is measured in the legs to exclude the possibility of
peripheral arterial disease. The upper arm cuff is applied
to the ankle and auscultation performed on the dorsalis
pedis or posterior tibial artery. A large cuff can be ap-
plied to the thigh, using a bladder that is 20% wider than
the diameter of the thigh (range, 15 to 18 cm). Ausculta-
tion is performed on the posterior tibial artery. Accurate
BP measurement is shown in Table 4. Because the mea-
sured value varies widely when the pulse is not regular,
BP should be measured at least three times [30].
Home blood pressure measurement
Automated device validated for the measurement of out-
of-office BP is more and more popular. Home BP is
known to be more accurate to predict CV outcomes and
cost-effective in HTN patients [31]. Home BP monitor-
ing becomes important in monitoring of BP during
treatment in addition to the diagnosis of HTN. Home
BP monitoring is useful to diagnose white coat HTN,
masked HTN, and resistant HTN and to titrate the
Table 4 Blood pressure measurement using auscultation
method
Standard Procedures of Blood Pressure Measurement
After resting for 5 or more minutes in a quiet, appropriate environment
Avoiding smoking, alcohol, or caffeine before measurement
Measuring 2 or more times at 1- to 2-min intervals in one visit
A cuff with a bladder at least 40% of arm circumference wide; 80% to
10% of arm circumference long (a standard bladder for adults: 13 cm
wide; 22 to 24 cm long)
Maintaining the upper arm cuff at the heart level
Inflating the cuff rapidly and deflating slowly at a speed of 2 mm Hg
per heart beat
Identifying the blood pressure as the systolic blood pressure at the
first Korotkoff sound; the blood pressure as the diastolic blood
pressure at the fifth Korotkoff sound
Regarding the blood pressure as the diastolic blood pressure at the
fourth Korotkoff sound in pregnancy, arteriovenous shunt, and
chronic aortic insufficiency
Taking blood pressure in both arms on the initial visit; subsequently
using the arm of higher pressure for measuring blood pressure
Taking blood pressure in legs to exclude peripheral arterial disease,
when pulses in the lower extremities are weak
Repeating the measurement three or more times to estimate the
average systolic and diastolic pressure in case of arrhythmia
Measuring BP after 1- and 3-min standing in elderly persons and
persons with diabetes and suspected orthostatic hypotension
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monitoring is known to improve the patient compliance
[32]. In general, home BP measured by standardized
method can be regarded as a substitute for ambulatory
BP. As shown in Table 5, the patient should be educated
for the validated device, the time of the day, frequency,
and period of measurement in addition to the standard-
ized method of home BP measurement [33]. MultimediaTable 5 Measurement of home blood pressure
Requirement Description
Upper arm cuff Wrist device is used only when extreme
obesity can cause error and the device
should be kept at the level of heart
Time of measurement 1. Morning: within 1 h after waking up,
after urination, before taking antihy
pertensive drugs, before breakfast,
after 5-min rest in a seated
position
2. Night: before retiring, after 5-min
rest in a seated position
3. Other conditions if necessary
Frequency of measurement One to three times per occasion
Period of measurement As long as possible; 1 week or more for
the diagnosis of hypertension; over at
least 5 to 7 days immediately
preceding the visit during follow-up
of treatmentis available at www.koreanhypertension.org. Home BP is
lower than clinic BP. HTN can be diagnosed when home
BP is 135/85 mm Hg or higher. When making a diagno-
sis of HTN, it is recommended to measure at least five
consecutive days in a week and one to three measure-
ments in each session in the morning and evening. In
the morning, it is measured after voiding, within 1 h
awakening, and before taking antihypertensive drugs. In
the evening, it is measured before sleep. When calculat-
ing mean BP, the reading on the first day usually are
omitted.
Ambulatory blood pressure measurement
Ambulatory BP measurement provides information on
the BP during the daytime, nighttime, and specific pe-
riods, for example, early morning. Measurement of BP is
performed at 15- to 30-min intervals over a 24-h period.
Ambulatory BP measurement provides better prognostic
information than does BP measurement in the clinic
[34]. The mean daytime ambulatory BP criterion for
HTN is the same as for home BP, i.e., 135/85 mm Hg or
more (Table 6). Ambulatory BP measurement is useful
in clinical conditions such as white coat HTN, masked
HTN, resistant HTN, labile HTN, and autonomic dys-
function and also when accurate measurement of BP is
required for risk assessment [35]. HTN is regarded as
morning HTN when the BP value obtained by home or
ambulatory BP measurement in the morning hours is
135/85 mm Hg or more and is higher than those taken
before going to bed. Morning HTN is considered to be a
risk factor for cardiovascular disease (CVD), particularly
stroke [36]. BP shows a diurnal rhythm, being higher
during waking hours and lower during sleep. Normally,
the average BP is 10% to 20% lower at nighttime than
during the day (dipper). A difference of less than 10%
(non-dipper) or an increase in the nighttime BP relative
to the daytime BP (riser) is associated with increased risk
for death, myocardial infarction, and stroke [37]. A de-
crease of 20% or more (extreme dipper) may be associ-
ated with increased risk for ischemic stroke and
atherosclerosis [38]. Risers may have autonomic dysfunc-






Clinic or office blood pressure ≥140 ≥90
Ambulatory blood pressure
24 h ≥130 ≥80
Day ≥135 ≥85
Night ≥120 ≥70
Home blood pressure ≥135 ≥85
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instruct the patient to engage in his or her ordinary daily
activities but to avoid strenuous exercise and also to
hold the arm still and in extension during cuff inflation.
It is also necessary to educate the patient in how to keep
a diary and how to turn off the monitoring device.
Evaluation of the patient
Diagnosis and examination are aimed at: 1) differentiat-
ing primary and secondary HTN, 2) evaluating the se-
verity of HTN, 3) identifying CV risk factors and
lifestyle issues, and 4) searching for CVD, concomitant
disease, or subclinical target organ damage that could
affect the choice of treatment.
Symptoms and signs
Patients with HTN most often have no specific symp-
toms of high BP. High BP is usually found incidentally
when hypertensive patients seek health care for other
reasons or else is detected in conjunction with symp-
toms of hypertensive CVD or an underlying secondary
cause of HTN. Headache is often considered a symptom
of high BP. However, there is no link between high BP
and headache except in cases of severe HTN. Headache
accompanied by HTN is commonly localized to the back
of the head, occurs early in the morning upon awaken-
ing, and subsides spontaneously during the day. Some
patients with HTN exhibit general, non-specific symp-
toms of high BP such as dizziness, palpitation, fatigue,
and sexual dysfunction. The symptoms of hypertensive
CVD are hematuria, blurred vision, dizziness due to
transient cerebral ischemia, angina, and shortness of
breath due to heart failure. In some rare cases, chest
pain due to aortic dissection or aortic aneurysm can
occur. Patients with secondary HTN can have specific
symptoms and signs suggestive of the underlying cause.
For example, patients with sleep apnea syndrome may
experience early morning headache, excessive daytime
sleepiness, depression, reduced concentration, and noc-
turnal dyspnea. Patients with primary aldosteronism
may have polyuria, polydipsia, and episodes of muscle
weakness; those with Cushing’s syndrome, weight gain
and emotional instability; and those with pheochromocy-
toma, episodic headache, palpitation, sweating, and
orthostatic hypotension.
Medical history
The medical history includes: 1) personal history of
present illness, past history, and family history; 2) symp-
toms and signs suggestive of secondary causes of HTN;
3) symptoms and signs of target organ damage; 4) CV
risk factors; 5) concomitant diseases; 6) lifestyle factors
such as diet, smoking, alcohol consumption, physical ac-
tivity, exercise, sleep, and personality/psychological state;7) duration and previous level of high BP, previous treat-
ment and its results, and adverse effects of antihyperten-
sive therapy; 8) use of non-steroidal anti-inflammatory
drugs, oral contraceptives, herbs, and other drugs; and
9) socioeconomic status.
Physical examination
Physical examination of hypertensive patients includes:
1) measurement of BP in both arms at the first visit as
well as the pulse rate; 2) measurement of height and
weight to calculate the BMI as well as measurement of
waist circumference; 3) auscultation for bruits over the
carotid arteries, abdomen, and femoral arteries; 4) palpa-
tion of the thyroid; 5) examination of the heart and
lungs; 6) examination of the abdomen for kidney en-
largement, masses, bladder distension, and abnormal
aortic pulsation; 7) examination of the lower extremities
for edema and palpation of the pulses; and 8) neuro-
logical examination. Waist circumference is measured
with a tape measure at the level midway between the
lowest rib and the iliac crest with the patient in a stand-
ing position, at the end of normal expiration, with the
abdomen exposed and without compression of the ab-
dominal skin.
Laboratory examination
Laboratory examination is performed to identify add-
itional CV risk factors, secondary causes of HTN, sub-
clinical organ damage, and concomitant diseases.
Routine laboratory tests should be performed before an-
tihypertensive treatment. Other recommended and ex-
tended tests may be performed if necessary (Table 7).
Cardiovascular risk factors and subclinical organ
damage
HTN is typically accompanied by other CV risk factors,
so frequently so that reduction of BP alone is insufficient
to control the clinical risk for CV events [17]. In some
high-risk patients by the estimation of the global CV risk
or patients with organ damage, BP-lowering treatment
can be initiated even when the BP is below the diagnos-
tic cutoff for HTN. However, there is no risk stratifica-
tion tool specific for Korean patients with HTN. Table 8
shows the factors in addition to the BP level that are
used for evaluation of the risk for future CV events, such
as 1) risk factors: age, smoking, obesity, dyslipidemia, in-
creased fasting blood glucose, familial history of prema-
ture CVDs, and diabetes mellitus (DM); 2) signs of
subclinical organ damage: (micro)albuminuria, left ven-
tricular hypertrophy (LVH), retinopathy, atherosclerosis,
and increased arterial stiffness; and 3) clinical CVD:
cerebrovascular disease, heart disease, chronic kidney
disease (CKD), and peripheral vascular disease [40].
These predictors of the individual patient’s risk are very
Table 7 Laboratory examinations
Level Tests
Routine 12-lead electrocardiogram
Urinalysis: proteinuria, hematuria, glucosuria
Hemoglobin, hematocrit
K+, creatinine, estimated glomerular filtration
rate, uric acid, fasting glucose, lipids
(total cholesterol, high density lipoprotein




(in random urine sample)
Recommended 75 g oral glucose tolerance test or
hemoglobin A1c (when fasting




Ankle-brachial blood pressure index
Pulse wave velocity
Fundoscopy (mandatory in diabetes)
24-h urine protein excretion
Ambulatory blood pressure/home
blood pressure measurements
Extended Search for asymptomatic organ
damage: brain, heart, kidney, vessels
Search for secondary causes
of hypertension





Age (men ≥ 45 years old,
female ≥ 55 years old) Smoking
Obesity (body mass index ≥ 25 kg/m2)
or abdominal obesity (waist circumference
male > 90 cm, women > 80 cm) [41]
Dyslipidemia (total cholesterol ≥ 220 mg/dL,
low-density lipoprotein cholesterol ≥ 150 mg/
dL, high-density lipoprotein cholesterol < 40
mg/dL, triglycerides ≥ 200 mg/dL)
Impaired fasting glucose (100 ≤ fasting
blood glucose < 126 mg/dL) or impaired
glucose tolerance
A family history of premature cardiovascular
disease (men < 55 years old,
women < 65 years old)
Diabetes mellitus (fasting blood glucose ≥ 126
mg/dL, postprandial 2-h glucose (oral glucose
tolerance test) ≥ 200 mg/day, or




Brain: cerebrovascular accident, transient
cerebral ischemia, vascular dementiaHeart:
left ventricular hypertrophy, angina
pectoris, myocardial
infarction, heart failure
Kidney: microalbuminuria (range, 30 to 299 mg/
day), overt proteinuria (≥300 mg/day), estimated
glomerular filtration rate < 60 mL/min/1.73 m2,
chronic kidney disease
Blood vessel: atherosclerosis, aortic disease,
peripheral vascular disease (ankle-brachial blood
pressure index < 0.9), carotid intima-media
thickness ≥ 1.0 mm, carotid-femoral pulse
wave velocity > 10 m/s
Retina: stage 3 or 4 hypertensive retinopathy
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therefore needed to develop a risk stratification system
specific for the Korean population.Risk stratification system of hypertension
The risk stratification of HTN in South Korea was based
on the KMIC data, which were drawn from patients with
the following characteristics: 1) registered in the early
1990s, 2) relatively young age range of 35 to 59 years,
and 3) relatively high socio-economic status. Therefore,
this stratification may have limitations including a ten-
dency to underestimate the absolute risk of HTN and lack
of representativeness of the entire population [42]. The
lowest CV event risk in the patients with HTN in the
KMIC data was 2% to 3% or 2.5% among the patients in
their 40s. According to the guidelines presenting risk group
by CV event rates [43,44], the average-risk group was those
patients with a risk approximately twofold higher than that
of the lowest risk group, corresponding to a 10-year CV
event rate of 5%. The moderate added risk group was de-
fined as the patients with a risk ≥twofold higher than that
of the average risk group, i.e., a 10-year CV event rate of
≥10%. The high added risk group was defined as the groupwith a risk ≥twofold higher than that of the moderate
added risk group, i.e., a 10-year CV event rate of ≥20%.
Therefore, the 10-year CV event rates for the lowest,
average, low added, moderate added, and high added
(including highest added risk group) risk groups were
2.5%, 5%, 5% to 10%, 10% to 15%, and ≥15%, respect-
ively, after consideration of the potential underestima-
tion; these levels correspond to the CV event rates of
2.5%, 5%, 5% to 15%, 15% to 20%, and 20% in the European
guidelines [43-45].
In the risk table derived from the KMIC data shown in
the Korean Society of Lipidology and Atherosclerosis
guideline for the treatment of dyslipidemia 2009 [42],
patients with stage 1 HTN who are in their 40s and have
no other CV risk factors have a risk of 4.3% to 5.3%;
some of them may be at above average risk, whereas the
women in this group are at below average risk, i.e., 4.0%
to 4.9%. Although the age in the risk table was blocked
in 10-year units, preventing observation of any gradual
Table 9 Stratification of global cardiovascular risk in hypertension patients







No risk factora Lowest risk group Low added risk group Moderate to high added risk group
Risk factor other than DM: 1–2 Low to moderate added risk group Moderate added risk group High added risk group
Risk factor ≥ 3 or subclinical organ damage Moderate to high added risk group High added risk group High added risk group
DM, cardiovascular diseases, chronic
kidney disease
High added risk group High added risk group High added risk group
DM diabetes mellitus.
aRisk factors: age (men≥ 45 years old, female≥ 55 years old), smoking, obesity (or abdominal obesity), dyslipidemia, impaired fasting glucose or impaired glucose tolerance,
family history of premature cardiovascular disease, and diabetes mellitus. Ten-year cardiovascular event rates for the lowest, average, low added, moderate added, and high
added (including highest added risk group) risk groups were 2.5%, 5%, 5% to 10%, 10% to 15%, and ≥15%, respectively, according to Korean Medical Insurance Company
Study data.
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who were in their 50s were at clearly higher than average
risk. Therefore, among patients with HTN, men aged
45 years and women aged 55 years were considered to
be in the low added risk group. Within the limitation of
the imprecise age scale, age greater than those sex-
specific cutoff values was regarded as a risk factor. The
CV risk was 9.8% to 11% among subjects in their 50s
with SBP higher than 130 mm Hg and hypercholesterol-
emia who were smokers, meaning that even a patient
with only stage 2 prehypertension could be stratified as
at least moderate added risk if he/she has three risk fac-
tors. Subjects in their 60s with stage 2 prehypertensionTable 10 Clinical clues and diagnostic tests of secondary hyp
Diseases Clinical clues Laborat
































































Hyperglyand three risk factors clearly belong to the high added
risk group. However, further, better-designed prospective
observational studies are needed to provide a more rep-
resentative or clearer estimation of individual risk. The
CV risk can be stratified using the BP level, number of
risk factors, evidence of subclinical organ damage, and
clinical CVDs, as shown in Table 9.
Symptoms of and screening tools for secondary
hypertension
Secondary HTN can be diagnosed in approximately 5%
of all patients with HTN. Additional testing should be
performed when the pretest probability is lower than theertension
ory test
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cemia Cortisol in 24-h urine Dexamethasone
suppression test
Shin et al. Clinical Hypertension  (2015) 21:1 Page 10 of 11sensitivity of the screening tests, as in the following cases:
1) secondary HTN suggested by age, medical history, phys-
ical examination, basic laboratory examination, and the se-
verity of HTN; 2) poor response to antihypertensive drugs;
3) BP resistant to previously effective treatment for no ap-
parent reason; and 4) sudden onset of HTN. In some cases,
secondary HTN can be cured by surgery or drug therapy.
Renovascular HTN is a possibility among patients with
HTN beginning at an age of <30 or >55 years, worsening of
previously well-controlled HTN, an abdominal bruit, resist-
ant HTN, an increase in the creatinine level of >30% over
the baseline level following the administration of an angio-
tensin converting enzyme (ACE) inhibitor or angiotensin II
receptor blocker (ARB), and the presence of atherosclerotic
disease in other organs. Screening for renovascular HTN is
performed by using the captopril renal scan, Doppler ultra-
sound, computed tomography, or magnetic resonance angi-
ography. Hyperkalemia with no apparent cause or an
incidentally diagnosed adrenal mass are indications for
evaluation for hyperaldosteronism. Because paroxysmal
and/or refractory HTN accompanied by hyperadrenergic
symptoms suggests the possibility of pheochromocytoma,
measurement of the catecholamine level in the plasma
and/or 24-h urine, CT, magnetic resonance imaging, or
radioisotope imaging (I-131 metaiodobenzylguanidine) is
indicated (Table 10). In recent years, sleep apnea syndrome
has been suggested as the leading cause of secondary HTN,
but no treatment strategy for high BP associated with sleep
apnea syndrome has yet been established [46].
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